Orchid Pharma Exblifep Deal, October 24, 2026: Libra to Take the Antibiotic Into Nine Latin American Markets

Orchid Pharma has signed its first licensing and supply deal for Exblifep in Latin America. In a filing to the exchanges on Saturday, October 24, 2026, the Tamil Nadu-registered antibiotics maker said Uruguay-based Laboratorio Libra will take the Orchid Pharma Exblifep combination (cefepime/enmetazobactam) into nine markets in the region, with Orchid making the product and Libra selling it.

It isn’t a big-ticket number by pharma standards. But it is one more step in taking India’s first home-invented new antibiotic beyond the US and Europe, and that’s why it’s worth a closer look.

What the Orchid Pharma Exblifep deal covers

According to the press release Orchid filed with NSE, Libra gets exclusive rights to register, import and market Exblifep in Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay and Uruguay. Orchid keeps the manufacturing and will supply the finished dosage form.

The headline figure: over the first 10 years, the partnership is expected to be a potential commercial opportunity of about USD 80 million, based on projected demand across those nine countries. Spread evenly, that works out to roughly USD 8 million a year, but that is only a simple average; the company has not given a year-by-year split. The filing also doesn’t say how that opportunity is divided between Orchid’s supply revenue and Libra’s sales.

There’s an important condition too. Commercial launch in each country needs approval from that country’s own drug regulator, so none of this revenue is switched on yet.

Why Exblifep matters to Orchid

Exblifep is used for complicated urinary tract infections and for hospital-acquired and ventilator-associated pneumonia caused by Gram-negative bacteria. The company pitches it as a carbapenem-sparing option against infections driven by ESBL-producing bacteria, a class of drug-resistant bacteria.

The filing says the drug is approved by both the US Food and Drug Administration and the European Medicines Agency, appears in the IDSA and EUCAST treatment guidelines, and is the first new chemical entity invented by an Indian pharmaceutical company to win both approvals. Orchid says the product is already commercially marketed in Europe and India.

Managing Director Manish Dhanuka called the Latin America expansion “a priority for Orchid” in the release. Libra, founded in Uruguay in 1961, works in infectology, critical care, oncology and other specialist areas, which is the hospital channel an injectable antibiotic needs. Sathguru Management Consultants advised Orchid on the transaction.

How to read it

We’d see this as a model the company can repeat rather than a stock-moving event on its own. Orchid makes and ships the product, a regional partner with local regulatory muscle does the registration and selling, and Orchid avoids building a sales force in nine small markets. The risk sits in the timelines: each country’s approval can take its own time, and the USD 80 million is a projection over a decade, not a contract value.

The filing came on a Saturday, so Monday, October 26, is the first session where the market can react. Investors following Indian drugmakers’ new approvals may also want to read our pieces on the Zydus USFDA approval and Dr Reddy’s Zytorvi DCGI approval.

What to watch next: the first regulatory approval in any of the nine countries, and whether Orchid gives any revenue guidance for Exblifep outside Europe and India in its next quarterly update.

Disclaimer: This article is for information and education only and is not investment advice. Please do your own research or consult a SEBI-registered adviser before making any investment decision.